Search company, investor...

Predict your next investment

Prime Movers Lab company logo
Venture Capital
primemoverslab.com

Investments

66

Portfolio Exits

3

Funds

21

About Prime Movers Lab

Prime Movers Lab invests in scientific startups founded by Prime Movers. It invests in companies focusing on energy, transportation, infrastructure, manufacturing, agriculture, and human augmentation. The company was founded in 2018 and is based in Jackson, Wyoming.

Headquarters Location

320 East Broadway

Jackson, Wyoming, 83001,

United States

Are you an investor?
Submit your portfolio details now to be considered in our investor rankings.

Latest Prime Movers Lab News

LyGenesis: $19 Million Closed To Develop Cell Therapies

Oct 31, 2023

LyGenesis – a clinical-stage biotechnology company developing cell therapies for patients with end-stage liver disease, type 1 diabetes, end-stage renal disease, and aging – recently announced it had raised more than $19 million in a Series A-2 financing round led by Prime Movers Lab, investors in breakthrough scientific startups, with follow-on funding from Juvenescence. This funding round will enable LyGenesis to complete its Phase 2a clinical trial (ClinicalTrials.gov Identifier: NCT04496479) and advance its pipeline of cell therapies. Lygenesis hepatocytes are engrafted into the lymph node, where they can proliferate and form a functioning ectopic liver inside the body. KEY QUOTES: “LyGenesis’s regenerative cell therapies have the potential to transform the lives of patients who are either medically ineligible for an organ transplant or are awaiting an organ to become available. Using lymph nodes as bioreactors to grow ectopic organs is the type of platform technology that could revolutionize the treatment of multiple diseases and beneficially affect millions of lives.” — Justin Briggs, Biologist and Partner at Prime Movers Lab, who will be joining LyGenesis’s Board of Directors “We’re delighted to continue our support for LyGenesis on its mission to restore the function of failing vital organs. By combining allogeneic cells from donated but discarded organs with a cost effective manufacturing process and engrafting their cell therapies using a low risk outpatient endoscopic ultrasound procedure, LyGenesis represents a truly remarkable opportunity.” — Richard Marshall, Chief Executive Officer of Juvenescence. The Series A-2 financing was also supported by Juvenescence and other investors Sponsors

Prime Movers Lab Investments

66 Investments

Prime Movers Lab has made 66 investments. Their latest investment was in Paradromics as part of their Series A - II on November 11, 2023.

CBI Logo

Prime Movers Lab Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

11/1/2023

Series A - II

Paradromics

$17.13M

No

1

10/12/2023

Series A - III

LyGenesis

$19M

Yes

Juvenescence, and Undisclosed Investors

5

9/12/2023

Series B

Lyten

$200M

Yes

4

6/27/2023

Seed VC - II

Subscribe to see more

$99M

Subscribe to see more

10

6/22/2023

Series A

Subscribe to see more

$99M

Subscribe to see more

10

Date

11/1/2023

10/12/2023

9/12/2023

6/27/2023

6/22/2023

Round

Series A - II

Series A - III

Series B

Seed VC - II

Series A

Company

Paradromics

LyGenesis

Lyten

Subscribe to see more

Subscribe to see more

Amount

$17.13M

$19M

$200M

$99M

$99M

New?

No

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Juvenescence, and Undisclosed Investors

Sources

1

5

4

10

10

Prime Movers Lab Portfolio Exits

3 Portfolio Exits

Prime Movers Lab has 3 portfolio exits. Their latest portfolio exit was Energy Vault on February 14, 2022.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

2/14/2022

Reverse Merger

$99M

5

12/31/2021

Reverse Merger

Subscribe to see more

$99M

Subscribe to see more

10

10/7/2020

Acq - Pending

Subscribe to see more

$99M

Subscribe to see more

10

Date

2/14/2022

12/31/2021

10/7/2020

Exit

Reverse Merger

Reverse Merger

Acq - Pending

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Sources

5

10

10

Prime Movers Lab Fund History

21 Fund Histories

Prime Movers Lab has 21 funds, including Prime Movers Lab Early-Stage Fund III.

Closing Date

Fund

Fund Type

Status

Amount

Sources

7/26/2023

Prime Movers Lab Early-Stage Fund III

$245M

1

1/20/2022

Prime Movers Lab Fund III

$186M

1

1/27/2021

Prime Movers Lab Fund II

$245M

2

12/29/2020

Boom PML SPV 1

10

11/25/2020

Turntide PML SPV 1

$99M

10

Closing Date

7/26/2023

1/20/2022

1/27/2021

12/29/2020

11/25/2020

Fund

Prime Movers Lab Early-Stage Fund III

Prime Movers Lab Fund III

Prime Movers Lab Fund II

Boom PML SPV 1

Turntide PML SPV 1

Fund Type

Status

Amount

$245M

$186M

$245M

$99M

Sources

1

1

2

10

10

Prime Movers Lab Team

6 Team Members

Prime Movers Lab has 6 team members, including current Founder, General Partner, Dakin Sloss.

Name

Work History

Title

Status

Dakin Sloss

Founder, General Partner

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Name

Dakin Sloss

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Work History

Title

Founder, General Partner

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.